Guangdong Xiangxue Precision Medical Technology Co., Ltd   Report issue

For profit Phase 1
Founded: Guangzhou China (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2017
NCT03029273
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Guangdong Xiangxue Precision Medical Technology Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Esophageal Neoplasms (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasms (Phase 1)

Osteosarcoma (Phase 1)

Sarcoma (Phase 1)

Soft Tissue Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 4